Scibase AB - Asset Resilience Ratio
Scibase AB (SCIB) has an Asset Resilience Ratio of 43.33% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Scibase AB's Asset Resilience Ratio has changed over time. Check how strategically is Scibase AB's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Scibase AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Scibase AB (SCIB) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr22.60 Million | 43.33% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr22.60 Million | 43.33% |
Asset Resilience Insights
- Very High Liquidity: Scibase AB maintains exceptional liquid asset reserves at 43.33% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Scibase AB Industry Peers by Asset Resilience Ratio
Compare Scibase AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Bactiguard Holding AB (publ)
ST:BACTI-B |
Medical Devices | 8.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
Annual Asset Resilience Ratio for Scibase AB (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Scibase AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.33% | Skr22.60 Million ≈ $2.43 Million |
Skr52.17 Million ≈ $5.61 Million |
+25.11pp |
| 2024-12-31 | 18.22% | Skr11.24 Million ≈ $1.21 Million |
Skr61.73 Million ≈ $6.64 Million |
-34.82pp |
| 2023-12-31 | 53.04% | Skr34.12 Million ≈ $3.67 Million |
Skr64.33 Million ≈ $6.92 Million |
+15.26pp |
| 2022-12-31 | 37.77% | Skr18.83 Million ≈ $2.03 Million |
Skr49.85 Million ≈ $5.37 Million |
-39.00pp |
| 2021-12-31 | 76.77% | Skr65.61 Million ≈ $7.06 Million |
Skr85.46 Million ≈ $9.20 Million |
+6.86pp |
| 2020-12-31 | 69.92% | Skr41.43 Million ≈ $4.46 Million |
Skr59.25 Million ≈ $6.38 Million |
+12.61pp |
| 2019-12-31 | 57.31% | Skr26.46 Million ≈ $2.85 Million |
Skr46.16 Million ≈ $4.97 Million |
-25.92pp |
| 2018-12-31 | 83.23% | Skr67.51 Million ≈ $7.27 Million |
Skr81.11 Million ≈ $8.73 Million |
-2.77pp |
| 2017-12-31 | 86.01% | Skr110.02 Million ≈ $11.84 Million |
Skr127.91 Million ≈ $13.77 Million |
+2.81pp |
| 2016-12-31 | 83.20% | Skr84.95 Million ≈ $9.14 Million |
Skr102.11 Million ≈ $10.99 Million |
+78.75pp |
| 2012-12-31 | 4.45% | Skr1.06 Million ≈ $114.31K |
Skr23.87 Million ≈ $2.57 Million |
-- |
About Scibase AB
SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin c… Read more